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O r i g i n a l  A r t i c l e s
Effects of Insulin on Vascular Tone and Sympathetic 
Nervous System in NIDDM
W
J o s  A. L u tte rm a n
M f c  f T W v r r r y
Chronic activation of the sympathetic nervous system 
may be a pathogenetic mechanism by which liyperinsu- 
linemia induces cardiovascular damage in insulin-resis­
tant NIDDM patients. The influence of physiological 
hyperinsulinemia ( 700 pmol/l) on basal and stimulated 
sympathetic outflow was studied in 12 lean normotensive 
subjects with well-controlled NIDDM without complica­
tions and in 13 matched control subjects. Forearm blood 
llow (FBF) was measured with forearm plethysmography; 
sympathetic nervous system activity was assessed by the 
[‘TI]norepinephrine (NE) tracer method* NIDDM patients 
were insulin resistant (glucose infusion rates 31.8 ± 3.8 
vs. 48.7 ± 2.0 fjunol • kg ' 1 4 min 1 in control subjects, P < 
0.01). After a mixed meal, NIDDM patients showed a 
hyperinsulinemic response (2-h insulin levels; NIDDM 
patients 321 ± 31 pmol/l, control subjects 165 ± If) 
pmol/l, P < 0.001). Insulin infusion induced a vasodilator 
response (not significantly different between the 
groups). Arterial plasma NE levels and total-body NE 
spillover increased significantly (total spillover in 
NIDDM patients from 0.77 ± 0.09 to 1.18 ± 0.16 
nmol * m ~ • min in control subjects from 0,98 ± 0.14 to
1.23 ± 0.18 nmol m 2 min “1, P < 0.01 for all, not; 
different between groups). Total-body NE clearance did 
not change. Sympathetic stimulation (lower-body nega­
tive pressure [LBNP] 15 mmllg) induced forearm vaso­
constriction and increased arterial and venous plasma NE 
and total NE spillover. Responses of FBF and NE kinetics 
to LBNP were not significantly different between groups 
and were not altered by hyperinsulinemia. Although these 
nonobcsc subjects with uncomplicated NIDDM showed 
postprandial hyperinsulinemia and resistance to the ef­
fect of insulin on glucose metabolism, this group was not 
resistant to the vasodilator and sympathetic stimulant 
effects of insulin. Responses to sympathetic stimuli 
(LBNP) were normal and unaffected by physiological 
hyperinsulinemia. Therefore, because of daily life hyper­
insulinemia, chronic sympathetic stimulation could be 
operative in these patients and may explain the increased
incidence of hypertension and/or cardiovascular compli­
cations. Diabetes  45:15-22, 1990
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A s  a c o n se q u e n c e  o f  insulin res is tance , hyperinsu- 
linemia h a s  been  re la ted  to  d iso rd e rs  su c h  as 
hypertens ion , obesity , dyslipidemia, an d  NIDDM 
(1-3). F u r th e rm o re ,  hyperinsu linem ia  has been 
directly assoc ia ted  w ith  a th e ro sc le ro s is  and  ca rd iovascu la r  
events  (4 -0 ) .  The c a u se  o f  this re la tionsh ip  bet w een  hyper­
insulinemia and c a rd io v a sc u la r  m orb id ity  is no t clear, but it 
may be m edia ted  by so m e  ca rd io v ascu la r  effect o f  insulin. 
Besides insulin’s key role in the regulat ion o f  ca rb o h y d ra te  
m etabolism  (7), it has  b e c o m e  c lea r  tha t  it also has im portan t  
effects on the  c a rd io v a sc u la r  sy s tem  (8,9). In acu te  experi­
m en ts  in hum ans, insulin  in fusion  ex e r ts  a vasod ila to ry  e l le d  
( 1 0 , 1 1 ). In addition, acu te  hyper in su linem ia  induces  systciuh 
sym pathe tic  activation  a s  m e a su re d  by d irec t  m uscle  sy 1 
pathetic  nerve  activity  (MSNA) record ings  (11,12). Togo!' 
insulin-induced v aso d i la t io n  and  sym pathe tic  stimulat 
will induce  a  s ta te  o f  h y p e rd y n am ic  circulation, c h a ra c te r ­
ized by a high heart, ra te , w ide pu lse  p ressu re ,  and  increased  
card iac  output.  R ecen t  ep idem iological s tud ies , indeed, 
Rmncl a re la tionsh ip  b e tw e e n  a hyperdynam ic  circulation 
and  insulin res is tance  (13,14).
( ’ou tinuous  sy m p a th e t ic  s t im u la t ion  has been re la ted  to 
increased  ca rd io v ascu la r  m orb id ity  ( lfi), Chronic  s tim ulation  
o f  the sym pathe tic  n e rv o u s  sy s tem  due  to ch ron ic  hyperin- 
su linem ia could th e re fo re  be an im portant factor explaining 
the well-known in c re a se d  inc idence  o f  ca rd iovascu la r  dis­
ease that can  be o b se rv ed  in NIDDM p a t ien ts  ( lb).  Therefore , 
it seem s a  valid q u es t io n  w h e th e r  individuals w ith  chronic  
hyperinsulinem ia, w h ich  ho lds  true  for the initial phase  of 
NIDDM, a re  ex p o sed  to norm al insulin-induced sym pathe tic  
stimulation. In p a t ie n ts  w ith  long-standing es tab lished  
NIDDM, res is tance  to  the  vasod ila to ry  effects of insulin has 
been  rep o r ted  (17,18). Data on the  early  phase  of NIDDM are 
lacking, while e n d o g e n o u s  hyper in su linem ia  is most prom i­
nen t at th is  early s tag e  (19,20). M oreover, the ability of 
insulin to s t im ula te  sy m p a th e t ic  neural outflow in NIDDM 
has  not been  exam ined  before1.
In the present s tudy, w e  hypo thes ized  that NIDDM p a­
tients in the  early p h a se  o f  the ir  d isease  are  still sensit ive  to 
the  sym pathe tic  s t im ulan t effects o f  insulin. To a d d re s s  ou r  
hypothesis, sym pa the t ic  n e rv o u s  activity w as investigated  at 
baseline and  during  s t im u la t ion ,  b o th  before and  during
acute hyperinsulinemia, in patients with early mild uncom­
plicated NIDDM and well-matched healthy control subjects. 
To quantify the response of the sympathetic nervous system 
in detail, the [3H] norepinephrine (NE) tracer technique was
used (21).
r e s e a r c h  d e s i g n  a n d  m e t h o d s
Subjects. The study group consisted of 13 patients with NIDDM. All met. 
the inclusion criteria* age between 25 and 00 years, nonsmoking, 
absence of hypertension (office blood pressure <160/90 mmHg, mea­
sured after a 5-min rest in the supine position), absence of maciovas- 
cular and microvascular complications, as assessed by physical 
examination (normal tendon reflexes and normal vibration sense), 
normal ophthalmoscopic examination, normal renal function and albu­
min excretion rate (<20 |xg/min), body mass index <27 kg/nr, and good 
metabolic control (HbAlc <7.5%) with diet alone or low  doses of the 
first-generation sulfonylurea derivative tolbutamide ( ^ 1,000 mg/day). 
Participants used no other medication. Patients were recruited from our 
outpatient department (of —700 NIDDM patients* 11 met, the inclusion 
criteria, of whom 6 participated) and through calls for patients treated 
by general practitioners ('—SO candidates, of whom 7 w eie  included). Of 
the 13 patients, 10 had a family history positive for diabetes. One of 
these, who had NIDDM diagnosed before the age of 25 years, could be 
classified as having maturity-onset diabetes of the young and was 
excluded from further analysis because the etiology of this disease is 
different (22). Mean diabetes duration was 4 5  ± 6 .0  years (mean ± SD).
A control group consisted of 13 healthy, lean, normotensive, and 
nonsmoking (meeting the above-mentioned criteria) age- and sex- 
matched subjects. These participants were selected by advertisement 
and received a payment. All of these subjects had normal glucose 
tolerance and a family history negative for diabetes and hypertension. 
All participants gave written informed consent. The experimental pro­
tocol was approved by the hospital ethics committee.
Experim ental procedures and p rotoco l. Before the experiment, all 
participants underwent a mixed-meal test. After an overnight fast, they 
ingested a liquid meal containing 25 g proteins, 18 g lipids, and 72 g 
carbohydrates, partly disaccharides, including gelatin and fibers (total 
energy content 548 calories). Before and after 30j 60, 120, and 180 nun, 
blood samples were taken for plasma insulin and glucose determina­
tions.
Within 7 days after the mixed-meal test, the main experiment was  
performed after an overnight fast with the subjects in supine position in 
a quiet temperature-controlled room (25-26° C). Under local anesthesia 
(0.3-0.4 ml lidocaine HC1, 20 mg/ml), a 20-gauge catheter (Angiocath, 
Becton Dickinson, Sandy, Utah) was inserted into the left brachial artery 
and connected with an arterial pressure monitoring line (Viggo Spec- 
trained, 5269-129) to a Hewlett Packard 78353B monitor. In the sam e 
arm, a catheter (Venfion, 20 gauge, 32 mm) was inserted into a deep  
forearm vein to obtain venous blood samples. On the contralateral side, 
an identical catheter was inserted into a large forearm vein for the 
infusion of [3H]NE, insulin, and 20% glucose. After complete instrumen­
tation, at least 30 min of rest were included.
Previously prepared aliquots of [°H]NE were thawed and diluted with
0.9% saline to an activity of 4 i^Ci/ml. The weight o f  the syringe 
containing the radiotracer was measured just before and just alter the 
infusion to verify the infusion rate. At the end of the experiment, a 
portion of the radiotracer w as frozen and stored at -8 0 °C  for analysis at 
the time the plasma determination was performed. After a priming dose  
of 15 jxCi/m2, a continuous infusion of 0.35 |xCi ■ m “ 2 • min ' 1 [;,H]NE was 
given during the entire experiment. Again, 30 min were allowed to obtain 
a steady state, after which baseline hemodynamic and humoral m ea­
surements were performed. Then, lower-body negative pressure (LBNP) 
at - 1 5  mmHg, using a Perspex box, was applied for 15 min to stimulate 
the sympathetic nervous system (23). Subsequently, 30 min were again 
taken to allow all parameters to return toward baseline level The 
hyperinsulinemic euglycemic clamp was then started and w as continued 
for 90 min. During insulin infusion, hemodynamic data w ere obtained at 
20-min intervals and NE Idnetic measurements were obtained at 45 and 
90 min. Plasma insulin concentrations were measured after 60 and 90 
min. Finally, with the continuation o f insulin and glucose infusion, a 
second application of LBNP at - 1 5  mmHg was performed for 15 min. A  
schedule of the study protocol is shown in Fig. 1.
Forearm blood flow (FBF) was measured using mercury-in-Silastic 
® ? ^ S a u g e  venous occlusion plethysmography as previously described 
(24). One minute before the start of the measurements, a wrist cuff was
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FIG. 1. Time schedule of the experim ents performed.
inflated to 100 mmHg above systolic blood pressure. Tin* collecting cutV 
around the upper arm was inflated to a pressure of >10 mtnllg during 
eight heart cycles using a flokanson E20 rapid cull* iuUalor. The strain 
gauges were connected with Hokanson EtM plethysmographs.
Insulin (Actrapid, Novo Nordisk, Hagsvaerd, Denmark; 4UU 
pmol • m ~ * m iir 1 [00 mU • m ~ • min l |) was diluted in 50 ml 0 .0% NaCI 
with the addition of 2 ml of the patient’s plasma to a concentration o f i 
U/ml. Plasma glucose levels were kept at euglycemic levels by a variable 
infusion of 20% glucose solution, adjusted by arterial plasma glucose  
levels measured at fwnin intervals (25). During the last :U) min of the 
clamp, the glucose infusion rale w;is calculated in micromoles per 
kilogram per minute to obtain the whole-body glucose uptake, a 
measure of insulin sensitivity (26). Healthy subjects were dum ped at the 
fasting level; in diabetic patients, blood glucose was allowed to fall to a 
level of 5 muiol/l and kept there. In three patients, in whom no 
steady-state plasma glucose concentration was reached after tUl mm. the 
clamp was continued until HO min of steady state and lasted for a 
maximum of 120 min.
All studies were performed with the patients off medication. Of the 
diabetic patients, live used (low-dose) tolbutamide. This medication was 
stopped 7 days before the meal test and at least It) days b e f o r e  the 
experiment. The chance that gross hyperglycemia would develop v* as 
therefore minimal,
A nalytical m ethods. Plasma glucose was measured in duplicate by the 
glucose oxidation method (Beckman Glucose Analyzer 11, Heckman. 
Fullerton, CA) in arterial blood samples that were immediately centri­
fuged for 20 s. Plasma insulin was measured with a double antibody 
radioimmunoassay (interassay eoelllcient of variation [t'V| 0 .2%), It may 
be expected that this conventional insulin assay cross reacts with 
proinsulin and proinsulin-insulin split products (27), Therefore, the 
insulin samples before and after 120 min of the mixed-meal test were 
reanalyzed using the commercially available immunoiadtometrie insulin 
assay from Medgenix (Fleurus, Belgium). This assay show s no cross 
reactivity with proinsulin or ties 31,32 proinsulin (being the must 
important insulin split product's), Plasma (.‘-peptide was measured with 
a commercially available double-antibody radioimmunoassay UHugno* 
tic, Los Angeles) (interassay t'V '1.11%). llbAu. was measured usmg a 
high-performance liquid chromatography (IIPLO technique (BinKad. 
The Netherlands) with reference values of >l.K 0 .2%.
Tritialed norepinephrine (fm ^fring-^jW 'n (norepinephrine; spedUc  
activity 30-60  Ci/mmol) was obtained from Du Pout-NKN (‘s llertogeu  
bosch, The Netherlands). It. was sterilized using a micropore litter tu.22 
jxm) and diluted in 0 .0% N a d  containing glacial acetic add <0 2 m o th  
and ascorbic acid (1 mg/ml). Aliquots of 70 p t ’i/ml (;lll|NK were stored 
at; —80°C until use, which was always within ii months of preparation 
Sterilization, dilution, and batch dividing were carried out under nitro­
gen.
Blood samples for measurement of plasma catecholamines were 
collected in prechilled tubes containing glutathione (0.2 mol/U and 
EGTA (0.25 mol/I) on melting ice. The tubes wen* centrifuged at I t \  and 
plasma was stored at —H0°C; analyses of plasma samples and mfusatc 
occurred within 2 months of collection. Plasma samples were analyzed 
for concentrations of unlabeled and tritium-labeled NE by HPLC with 
fluorometric detection after precolunm dcrivatr/ation with the selective  
detection agent 1,2-diphenyIethylenediaminc. The laboratory procedure 
is a modification of an earlier described method (2H).
The instrumentation for the chromatography consisted of a model 010 
pump, a model 600E system controller, a model >170 scantling fluores­
cence detector (16-jxl flow cell), and an automated sample processor 
WISP 710B (all lrom Waters, Milford, MA). The separations were 
performed on a silica analytical Nova-Pak C‘lK (150 >: mm) cuhmm 
coupled to a Nova-Pak ClK guard column. The [:(II|NK activity was 
measured m the eluate collected for Im in  by a Gilson fraction collector 
(model 201-202) connected to the WI»^ 710B and programmed to start
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TABLE 1
Baseline characteristics of the two groups
4-.4 .  » • V *  •
n/  VW« v «f m  »» k <  4  I  • t
n
Systolic 1)1 ood pressure (mmllg)
Diastolic blood i)ressurc (nnuilg)
Basal flow (ml • dl 1 * min 1)
FV R (A U )
Fasting glucose (nuuol/1 1)
H1)A1(. (%)
Glucose infusion rate, (>0-4)0 min (juuol • kg 1 * min l )
* * '  V *
Data are m eans i: S I).
• »•**•/ r • '•A M  s . « » . »  m u  r f i *  >+ t
Diabetes
. r  -wW V f  ^  ,  4 w  ^  k  ^  ------- - - , , k  a ^ .
Normal
U+ * 4  » ' / •  • • •  ^  •  | | ■ 1 111 > > |  ■ !  ■!,»<! 1-----« k _  -----------------------
P  Viilue
1 2 13
5:7 5:8
4(),5 ±11.8 45.7 ±  G.0 NS
24.2 ± 2.5 24.2 ± 1.7 NS
130 ± 19 123 ± 1 1 NS
1)7 ± 10 (55 1 : 7 NS
2.80 ± 0 . 8 8 2.99 ± 1.25 NS
35.7 ± 12,1 35.2 ±  17.0 NS
8 . 8  ± 2 . 0 5.0 ± 0.4 < 0 . 0 0 1
0 . 8  ± 0 . 8 5,5 ± 0.5 < 0 . 0 0 1
31.8 ± 13.2 48,7 ± 0.9 < 0 . 0 0 1
» «  tws « I « *  '  ♦  f  • •
at the beginning of (ho NF peak position in the chromatogram of the 
standard solution, which was run before the plasma samples and [aH]NK 
infusate in each assay. The [:lII|NE activity of all I-ml tractionaled 
samples with 8  ml scintillation solution (Aqualuma) added was counted 
tor 20 min in a Packard Tri-Carb -UK) (\
Calculations and da ta  analysis. The following kinetic variables were 
calculated according to these formulas (2 1 )
Total clearance (1 • m ♦ min
( ¡illusion rate (dpm * m " * min )
[:'II|NE (dpni/1)
Total NK spillover (nmol • in ::,min M total clearance (Dm  “ * min *)
I NIC)»,,(nmol/1)
Forearm plasma How (FPF) (ml • dl FAV 1 * min l) 
{1 hematocrit) x FBF
r‘H|NK(ltl [-'HINFh,.,,
Fractional extraction (FM)
I'i i i n r HI
Forearm spillover (pmol • dl FAV 1• min l ) FPF x  ([NH]Vl,u
|NKL» KK-IN KL)
Forearm removal <pmol■dl FAV 1 * min 1) FPF x FE x (NK]
Forearm vascular resistance (FVR) was calculated by dividing mean 
arterial pressure by FBF and was expressed in arbitrary units (AD). 
Pulse pressure was calculated by subtracting diastolic from systolic 
blood pressure.
Since some parameters of NE kinetics showed a non-Gaussian 
distribution, statistical analysis of these data was performed using a 
nonparamolric paired analysis (Wiicoxon). The Mann-Whitney U test 
was used to compare the NE kinetic responses of diabetic patients with 
those of healthy individuals. Effects of insulin on hemodynamic param­
eters were calculated using repeated-mensures analysis of variance 
(ANOVA) w'ilh insulin as the dependent factor. All other (mainly 
metabolic) data met requirements of normality and were statistically 
analyzed with the Student’s t test. Correlations wore calculated using 
Spearman’s rank correlation test«. All statistical analyses were per­
formed using the SPSS personal computer software package,
Results in tables ami figures are expressed as means ± SE unless 
otherwise indicated. Statistical significance was set at P <  0.05.
RESULTS
Baseline measurements.
two groups are given in ' 
variables were not different
c *  ¥  *
.ti I levels and IIbA,„
characteristics of the 
1. Baseline hemodynamic 
between NIDDM patients and
TABLE 2
Responses of NE kinetic data to LBNP
Arterial NE (nmol/1)
NIDDM 
Control 
Venous NE (nmol/1)
NIDDM 
Control 
Total NE spillover
(nmol mu :l-min 1)
NIDDM 
Control 
Forearm NrF spillover 
(pmol’ dl 1 * min 1)
NIDDM
Control
Total NF clearance 
(nmol mu ;IMuin !)
NIDDM 
Control 
Forearm NE removal 
(pmol • dl 1 ♦ min l )
NIDDM
Control
4  ^  ,  ,
Data are means SE, *7* <0.05 
2 vs. insulin lit) min, UP
0.87 ►: 0.12
0.07 i  o.i;*
L31 0.28 
1.42 ♦ O.Ui
0.85 0.07 
0.89 0.03
1.18 0 . 2 0  
1.17 0 . 2 0
Baseline 1 LBNP 1
^  ^  *  ~A *•
Baseline 2
^  f  . s
. . » • •  4 • b .  •  »  ,
In.snliii
■in min
t t „  ,  /  *  f |  /  ,  f  .  . t +  ,  ^  ^  ^  a t  V*« 1  *
Insulin 
90 min
.  .  r w *  A *  *  A  < « l  > * •  w  # •  w i l t «  '  4  * • •  +  • *  *  #»  V  ♦  ■ « 1 «  ‘
LBNP 2
1 . 0 2  0 . 1 1 1.48 0.14t 1 . 0 1  ± 0 . 1 2 1.5(5 ± 0.1 (i§ 1.45 ± 0.10S 1 .8 U ± 0 .2 l||
1.05 * 0.12 l,H •*: 0.181* 1.14 ± 0.14 l.()(> ± 0.2:5S 1,54 ± 0.21S l.!H ± 0.1911
1.10 0.17 1.05 *. 0.231’ 1.27 :t 0.18 l.'K) ± 0 .2 0 ;!: 1.50 ± 0.22« 1.81 ± 0.27||
1,27 A 0.13 1.77 »: 0.14t 1.25 :t: 0.13 l.r>:t :t 0 ,1 (5:!: 1.44 ± 0.14# 2.13 ± 0.141
1.28 0 .2 2 t  
1.17 0.19*
0.77 t  0.09 
0.98 ± 0,14
1.15 ± 0.14:|: 
1.19 ± 0.17:1:
1.18 ± 0.108 
1.23 ± I  A V
1.24 0.30 
1 . 0 0  0 . 2 2
1.55 + 0.31 
1 . 2 0  ± 0.13
1.32 ±  0.89 
1.52 :t: 0.20
1.88 ± 0.30 
1.52 ± 0.22
0.85 :i: 0.12 
0.80 ;t: 0.05*
0.74 ± 0.05 
0.74 ± 0.05
0.81 ± 0.07 
0.S1 £  0.04
1.09 .1 : 0.10 
1.33 ± 0.25*
1.05 ± 0.20
1.13 ± 0.14
1.52 :t 0.20§ 
1.09 ±
± 0.22S
1.80 + 0.37§
, »  . * .  / « I .  A i  *  • 0 ,  . ^  . *  •- « 4 -* 4*** ^  .  «  » <•» * . V  * * -  -  >
1.29 ± 0.14 
1.42 ± 0,16
1.95 ± 0.31
0.73 ± 0,07 
0.76 ± 0.05
1.92 ± 0.32 
1.75 ± 0.35
(t/* * -:().()t ) LBNP 1 vs. bas(»line I, %P <0,05 mid §/J <0.01 insulin vs. baseline 2, ||P <0.05 (HP <0.01) LBNP 
Not(': Tht*re were no significant differences between the values of baseline 1 and those of baseline 2.
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FIG. 2. Response of plasma insulin concentrations during 180 min after 
a mixed meal as measured with the use of a conventional insulin assay 
(lines) and with a specific insulin assay (bars). *P < 0.05.
insulin concentration was higher in NIDDM patients (106 ±
0,02), as was
±  0 . 0 2
17 vs. 63 ± 6 pmol/1 in control subjects, P = 
fasting plasma C-peptide level (0.59 ± 0.07 vs. 0.40 
nmol/1 in control subjects, P < 0.02). Baseline NE kinetic 
parameters (arterial and venous plasma concentrations, to- 
tal-body and forearm spillover, total-body clearance, and 
forearm removal) were not different between NIDDM pa­
tients and control subjects (Table 2).
Responses to a mixed meal. In control subjects, the 
standardized mixed meal induced a slight increase in plasma 
glucose values, from 5.0 ± 0.1 to maximal 6.0 ± 0.2 mmol/1. 
NIDDM patients showed a more pronounced and prolonged 
increase of glucose levels, from 8.8 ± 0.6 to maximal 13.4 ±
1.2 mmol/1 after 60 min and to 9.4 ±1.1 mmol/1 after 180 min. 
The insulin response to a mixed meal was delayed in NIDDM 
patients, and on every time point it was larger than in control 
subjects (Fig. 2, lines). When expressed as area under the 
insulin curve, the responses in NIDDM patients were signif­
icantly increased compared with those in control subjects 
(58.0 ± 7.3 vs. 37.0 ± 3.7 nmol • F 1 • min-1, P < 0.02). Also, 
when measured with a more specific insulin assay, NIDDM 
patients had higher insulin levels than control subjects 
(baseline: 80 ± 15 [NIDDM] vs. 51 ± 5 pmol/1 [control], P — 
0.08; 120 min: 269 ± 33 [NIDDM] vs. 133 ± 19 pmol/1 
[control], P - 0.001) (Fig. 2, bars).
Metabolic response to euglycemic clamp. Blood glucose 
values during the last 30 min of the clamp were stable in all 
individuals (mean glucose concentration 4.9 ± 0.1 [NIDDM] 
vs. 4.9 ± 0.1 mmol/1 [control]; CV 4.8 ± 0.5% [NIDDM] and 4.3 
±0.5% [control]). After 60 min, plasma insulin concentration 
was 746 ± 65 pmol/1 in NIDDM patients and 645 ± 36 pmol/1 
in control subjects (P = 0.18), After 90 min, it was 810 ± 50 
pmol/1 in NIDDM patients and 645 ± 50 pmol/1 in control 
subjects (P <  0.05). Whole-body glucose uptake was signif­
icantly different between NIDDM patients and control sub­
jects (31.8 ± 3.8 vs. 48.7 ± 2.0 ¡jimol • kg"1 • min“1, P <  0.01). 
Effects of insulin on hemodynamic parameters. As indi­
cated in Fig. 3, 90 min of hyperinsulinemia induced a forearm 
vasodilation (FBF: 2.75 ± 0.23 to 3.90 ± 0.40 ml * min“1 • dl-1 
[NIDDM] vs. 2.98 ± 0.36 to 3.82 ± 0.56 ml • min”1 • dl-1 
[control], bothP < 0,05 by ANOVA) accompanied by a clear 
decrease of peripheral resistance (FVR: 36.9 ± 3.1 to 26.9 ±
3.2 [NIDDM] vs. 35.1 ± 4.6 to 27.2 ± 3.1 AU [control], both P
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FIG. 3. Time course of FVR, pulse pressure, and heart frequency during 
tlie entire experiment. *P < 0.06 compared with baseline I; < 0.05 
during insulin (ANOVA); 1fP < 0.05 compared with end of insulin 
infusion.
< 0.01). Systolic blood pressure did not change significantly 
and diastolic blood pressure decreased significantly in con­
trol subjects (from 66.3 ± 2.0 to 65.1 ± 2.1 nnnllg, P < 0,01), 
but not in NIDDM patients (from (58.0 ± 2,4 to 60.7 ± 3.0 
mmHg, P = 0.09). Pulse pressure increased in both groups 
(64.6 ± 2,9 to 66.6 ± 2.9 [NIDDM] vs. 58.1 ± 1.9 to 63.1 ± 1.8 
mmHg [control], both P < 0.05). Heart rate tended to 
increase significantly only in NIDDM patients (03.3 ± 1,8 to 
69.0 ± 2.3 bpm, P < 0,01) and not in control subjects (60.7 :l 
2.4 to 61.5 ± 2.5 bpm, P = 0.14), Responses of heart rate, 
pulse pressure, and FVR to the hyperinsulineinic clamp are 
depicted in Fig. 3.
There were no significant differences in hemodynamic* 
parameters between NIDDM patients and control subjects at 
different time points; nor were there significant differences in 
hemodynamic responses to insulin.
Effect of insulin on NE kinetics. Absolute NE kinetic data 
for the entire experiment are given in Table 2. During insulin 
infusion, arterial and venous NE concentrations increased 
(percentage increases after 45 and 90 min: arterial NE in 
NIDDM patients 62.8 ± 14.0 and 49.8 ± 10.4%, in control 
subjects 41.3 ± 9.1 and 33.5 ± 6.1%, P < 0.01 vs. baseline for 
all; venous NE in NIDDM patients 17.0 ± 4.8 and 22.4 £  6.7%, 
in control subjects 26.8 ± 8.3%, allP < 0.01, and 21.3 :t 7.7%», 
P < 0.05 vs. baseline).
Calculated total-body NE spillover increased (percentage 
changes after 90 min: 51.8 ± 9.4% [NIDDM] vs. 26,5 ± 7.0%
is
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FIG. <1, Absolute changes of arterial NE, total-body NE spillover, and 
total-body NE clearance during LBNP, insulin alone, and application of 
LBNP during insulin, N ,  NIDDM patients; I ‘ 1, control subjects. *P <
0.05 for LBNP compared with baseline 1, Tor insulin alone with baseline 
2, and for the combination with the end of the insulin infusion (Table 2).
[control], P  <  0,01 for both), Total-body NE clearance did 
not change during hyperinsulinemia (percentage changes 
after DO min: 3.7 ± 0.5% [NIDDM], P  -  0.51, vs. -5 ,1  ±  5.5% 
[control), NS lor both).
Forearm NE spillover increased (percentage changes after 
1)0 min: -17.!) ± 21.2% [NIDDM], P <  0.05, vs. 32.4 ±  18.0% 
[control], P  0.00), as did forearm 'N E removal (percentage 
changes after IK) min: 117..1 J: 35.8% [NIDDM] vs. 57.9 ±  
25.0% [control), P * 0.01 lor both).
The' quantitative responses  to insulin were not significantly 
different. be tw een  NIDDM patients  and control subjects  
(Figs. 4 and 5).
E ffec t  o f  LBNP. LBNP induced vasoconstriction (FVE: 30.f) 
± 4.5 to 4S.7 8 . 5  A t Î [NIDDM) vs. 34,7 ± 4.0 to 40.0 ±  0.5 
AT I [control], P < 0,05 for both) without affecting blood 
pressure» and heart rate (Fig. 3). Responses of NE kinetics to 
LBNP are  denoted  in Table 2. Arterial and venous NE as well 
as total-body NE spillover increased significantly, and fore­
arm NE spillover rem ained unchanged (Figs. 4 and  5). 
Responses in NIDDM patient« wore not different from those 
in control subjects. After this first LBNP, all param eters  
returned to baseline values, as  can also be  seen in Table 2. 
E ffec t  o f  h y p e r h i s u l in e m ia  o n  LBNP re s p o n s e s ,  Three 
NIDDM patients  developed presyncopal symptoms of dizzi­
ness anti nausea  during the second  LBNP, which w as then 
interrupted. Hypoglycemia w as excluded. Blood samples of 
these sub jec ts  taken ju s t  before the interruption w ere  not 
used in the* analysis. If they were used, however, the conclu­
sions would be the same.
In addition, during hyperinsulinemia, LBNP induced vaso­
constriction (FVR in NIDDM patients  [v = 0] 24.1 ±  3.0 to 
34.0 ± (U AU and in control subjects  27.2 ± 3.0 to 45.7 ±  9.5 
AU, P < 0,05 for both), w ithout changes in blood p ressure
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FIG. 5. Absolute changes of venous NE, forearm NE spillover, and 
forearm NE removal during LBNP, insulin alone, and application of LBNP 
during insulin. HI, NIDDM patients; CZ1, control subjects* V'P < 0.05 for 
LBNP compared with baseline 1, for insulin alone with baseline 2, and 
for the combination witli the end of the insulin infusion (Table 2).
and heart rate (Fig. 3). Arterial and venous NE increased 
(Table 2 and Figs. 4 and 5), and total-body NE spillover 
tended to increase, but; not; significantly. Baseline levels at 
the start of this LBNP were higher (previous insulin effect;), 
but; absolute responses to LBNP on both occasions were not 
different. Here again, the t wo study groups responded simi­
larly.
Control experim ents. In four young healthy volunteers 
(age 23.8 ± 0.3 years, BMI 20.8 ± 0,5 kg/nr), control 
experiments were performed. These individuals were stud­
ied with an intra-arterial line, but did not undergo any 
intervention and did not receive any infusion. At the respec­
tive time periods, blood samples were taken and blood flow 
and blood pressure were measured. During the 3-h experi­
ment, blood flow, vascular resistance, and arterial and ve­
nous plasma NE concentrations remained at a fairly constant 
level (baseline 1 to LBNP 1: FVR 48.2 ± 7.3 to 47.6 ± 8.1 AU, 
arterial NE from 0.82 ± 0.09 to 0.73 ± 0.13 nmol/1; baseline 2 
to insulin 90 min: FVR 51.4 ±7.1 to 01.7 ± 4.9 AU, arterial NE 
from 0,77 ±  0.14 to 0.91 ±  0.13 nmol/1; insulin 90 min to 
LBNP 2: FVR 71.7 ± 4,9 to 56.3 ± 3.5 AU, arterial NE from 
0.91 ± 0.13 to 0.94 ± 0.15 nmol/1).
DISCUSSION
The major new finding of the present study is that patients 
who are in the early phase of NIDDM show preserved 
vasodilator and sympathetic responses to physiological hy­
perinsulinemia. Moreover, on top of this preserved cardio­
vascular response to insulin, these NIDDM patients exhibit 
normal cardiovascular responsiveness to an exogenous sym­
pathetic stimulus, this being in our study the application of
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LBNP. In contrast, this group was resistant to the effect of is not necessarily the same as the rate of NE release from
insulin on glucose metabolism and was hyperinsulinemic 
after a regular meal. These observations imply that NIDDM 
patients at this early stage of their disease might be exposed 
to insulin-induced vasodilation and sympathetic stimulation
because of their hyperinsulinemia throughout the day. We 
speculate that the combination of increased skeletal muscle 
blood flow and increments in heart rate and pulse pressure, 
reflecting a hyperdynamic state, could be important in the 
development of hypertension and/or cardiovascular compli­
cations later in the course of the disease.
Metabolic effects of insulin. Most NIDDM patients pass 
through prediabetic and early diabetic stages (20), charac­
terized by high fasting and postprandial insulin levels (19,29) 
with concomitant existence of insulin resistance (30). In this 
study, we tried to select a group with very early NIDDM, 
maldng it as homogeneous as possible by using strict selec­
tion criteria. This patient group is exceptional from a clinical 
point of view; in most patients, the diabetic state is more 
advanced and patients are obese and have complications or 
comorbidity. Our nonobese NIDDM subjects were indeed 
insulin resistant, as has been reported before (31). Insulin 
sensitivity was assessed before the second LBNP and a 
sufficient time after the first LBNP to allow all parameters to 
return to baseline; hence, the determination of insulin sen­
sitivity could not be influenced by these sympathetic stimu­
latory procedures.
In NIDDM, proinsulin and proinsulin-split products have 
been found to be elevated (32,33) and may explain part of the 
measured hyperinsulinemia (27,34). However, using a spe­
cific insulin assay, we were still able to demonstrate that our 
NIDDM group showed true hyperinsulinemia, as were others 
(19).
Vasodilator response to insulin. Since 1990, a number of 
groups have demonstrated the vasodilatory effect of sys­
temic hyperinsulinemia (10,11,35). In NIDDM patients, 
Laakso et al. (17) have reported a decrease in insulin-induced 
vasodilation, partly reversible by improving metabolic con­
trol with insulin therapy (18). The reported studies, however, 
concern individuals with long-standing established diabetes 
who are in poor metabolic control and are considerably 
obese. This may be an important drawback because, as 
mentioned above, in NIDDM, endogenous hyperinsulinemia 
can be found especially in the early phase of the disease. 
Furthermore, insulin-induced vasodilation is attenuated in 
obesity itself (10,36). Recently it has also been reported that 
insulin-induced vasodilation was preserved in NIDDM sub­
jects (37), a finding that is compatible with our results. 
Sympathetic stimulant effects of insulin. The relation­
ship between insulin and the sympathetic nervous system 
has been studied using variable techniques. Some studies 
have reported an increase in venous plasma NE concentra­
tions during insulin infusion (8,9,11), with the earliest report 
being from Gundersen and Christensen (38). The venous NE 
concentration, however, results from total NE production 
and clearance on the one hand, local production and removal 
on the other hand, and blood flow. By measuring not only 
venous but also arterial blood samples and by using tracer 
NE infusion (21), afar more detailed estimate of sympathetic 
neural activity is possible. It is, however, important to realize 
that the [ H]NE kinetic tracer technique represents only the 
rate by which NE is entering the plasma compartment, which
20
sympathetic nerve endings.
With the use of microneurographic, readings (MSNA), the 
insulin-induced increase in sympathetic nervous system ac­
tivity has been quite consistently report ed (11,12,8^39). The 
MSNA technique has drawbacks ¿is well as advant ages. II- is 
technically demanding and is unsuccessful in a proportion of 
cases. Moreover, neural outflow at only one location is 
measured, which does not necessarily reflect; total sympa­
thetic activity. Until now, data on sympathetic responses in 
NIDDM patients have been sparse. As we show in our study, 
90 min of physiological hyperinsulinemia induced an in­
crease of total-body NE spillover. Since this spillover is an 
index of sympathoneural activity, our data indicate that; 
hyperinsulinemia induces sympathoneural stimulation. This 
sympathetic stimulation was of a moderate degree, around 
the same magnitude as stimulation induced by LBNP of -15  
mmHg. The insulin-induced sympathetic stimulation was 
clearly similar in both experimental groups.
Insulin concentrations during the clamp were, neverthe­
less, slightly higher in the NIDDM group, which is proba­
bly caused by a diminished insulin clearance, a feature 
coupled with insulin resistance (26,41,42). The difference 
in insulin level between the groups was small, however; 
furthermore, not only concentration but also duration of 
hyperinsulinemia seems to be important with respect to 
sympathetic stimulation (11). Finally, the relationship be­
tween insulin concentration and sympathetic stimulation is 
not linear; Vollenweider et al, (36) found comparable increases 
in sympathetic nerve activity (MSNA) despite threefold dif­
ferences in insulin concentrations. Probably sympathetic 
stimulation is already maximal at low insulin doses. There­
fore, it is highly unlikely that sympathetic responses in 
diabetic subjects would have been less if insulin concentra­
tions would have been more similar.
Response to sympathetic stimuli, The diabetic subjects in 
our study had normal responses to the non-insulin-sympa- 
thetic stimulus LBNP, despite higher prevailing glucose 
levels (fasting state, diabetes versus control). Also, insulin- 
resistant obese subjects have been reported to be normally 
responsive to sympathetic stimuli (Valsalva maneuver, cold 
pressor test, and baroreceptor activation and deactivation) 
(36,40), as have IDDM subjects (cold pressor test) (39). 
Recent work showed an increased response to hypoglycemia 
(to be considered as an intense sympathetic stimulation) in 
NIDDM (43). Thus, there is considerable evidence that, 
nonobese NIDDM patients have at least normal responses to 
sympathetic stimuli.
The response to the sympathetic stimulus LBNP was not. 
affected by acute hyperinsulinemia; baseline values just 
before the second test were indeed higher, but absolute 
changes were similar. These findings are in complete agree­
ment with the aforementioned studies of Vollenweider et al. 
(36), Grassi et al. (40), and Hoffman et. al, (39),
Mechanisms of sympathetic activation. While we confirm 
the vasodilatory and sympathetic stimulant effects of insulin, 
we are not able to explain the mechanism of these effects. If 
has been demonstrated previously that activation of the 
sympathetic nervous system is due to hyperinsulinemia and 
not to glucose infusion (44,45). Hypoglycemic episodes were 
avoided, so sympathetic activation cannot be due to glyco- 
penia. The observed sympathetic activation could be based 
on a baroreceptor reflex to a slight insulin-induced decline of
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blood pressure. This concept, in which vasodilation and 
sympathetic stimulation are coupled, is supported by the fact 
that in autonomous failure, insulin induces hypotension 
(46,47). From our data, it seems, however, that most of the 
sympathetic stimulation had already been established after 
45 min of insulin infusion, suggesting that the activation of 
the sympathetic nervous system is merely a predecessor 
rather than a consequence of the insulin-induced vasodila­
tion.
Pathophysiological implications. Since endogenous hy­
po llnsul in emia is indeed present in the fasting as well as in 
the postprandial state in our patients, we hypothesize that 
daily life hyperinsulinemia could induce a chronic stimula­
tion of the sympathetic nervous system. An increased sym­
pathetic drive lias been related to an increase in 
cardiovascular disease (15) and might in particular be rele­
vant to the development of hypertension.
Endogenous insulin levels are indeed linked to cardiovas­
cular risk in NIDDM subjects (48). One might speculate that 
as the disease proceeds, the chronic endogenous hyperinsu­
linemia could lead to an adaptive mechanism in which 
vascular and neurogenic responses are blunted. In support of 
this hypothesis are recent; epidemiological studies (13,14) in 
which a hyperdynamic circulation was predictive for the 
development of NIDDM (13). Also, in essential hypertension, 
an established state of insulin resistance and concomitant 
hyperinsulinemia (1), it is presumed that the initial hyperdy­
namic (hyperkinetic) circulation (15,41)) evolves into estab­
lished hypertension with increased peripheral resistance 
(50), With the use of the [:lIi)NE kinetic tracer technique, tin 
increased sympathetic* activation in response to insulin in 
hypertensive compared with normal subjects has been re­
ported (51), which may indicate that this group is at least not 
resistant to the sympathooxcitatory effect; of insulin.
However, we are not able to actually show this postulated 
increased sympathetic activity in our patients; nor can it be 
proved that hypertension eventually will develop. The alter­
native interpretation could be that insulin-stimulated sympa­
thetic neural activity is not involved in the pathogenesis of 
hypertension in NIDDM.
In conclusion, we report, that nonobese patients in the 
early phase of NIDDM, who are hyperinsuiiuemie and resis­
tant to the metabolic oiled, of insulin, are normally respon­
sive to the effects of insulin on vascular tone and 
sympathetic activity. Furthermore, the sympathetic nervous 
system is normally responsive to stimuli. This means that 
during daily life an excessive sympathetic neural outflow 
could exist. This fact could be an explanation for the 
increased incidence of hypertension and/or cardiovascular 
disease in this group and contribute to a hyperdynamic 
circulation» probably inducing secondary changes in time, 
Hyperinsulinemia did not change the absolute responses to 
sympathetic4 stimulation. The cardiovascular effects of insu­
lin warrant further investigation,
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